CARING FOR PATIENTS WITH CANCER:@0.084848:0.038601:0.499679:0.038601:0.499679:0.019343:0.084848:0.019343:0.019121:0.017404:0.014276:0.005315:0.017404:0.020508:0.006515:0.011406:0.020438:0.014276:0.006515:0.012154:0.015492:0.010019:0.005315:0.012606:0.017404:0.010019:0.011712:0.006515:0.022578:0.005315:0.010019:0.016063:0.006515:0.019121:0.017404:0.017404:0.019121:0.012606:0.014276
110:@0.018436:0.038809:0.050045:0.038809:0.050045:0.019212:0.018436:0.019212:0.010536:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
support, including primary care and spe-:@0.084242:0.096166:0.475150:0.096166:0.475150:0.080410:0.084242:0.080410:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.005330:0.007697:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.007703:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.007716:0.012450:0.013143:0.005713:0.012508:0.007703:0.013143:0.011738:0.013181:0.007705:0.007466:0.013123:0.012508:0.006388
cialist palliative care, as required.:@0.084242:0.112557:0.394586:0.112557:0.394586:0.096801:0.084242:0.096801:0.012450:0.003848:0.013143:0.003848:0.003848:0.007466:0.006523:0.005330:0.013123:0.013143:0.003848:0.003848:0.003848:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.012450:0.013143:0.005744:0.012508:0.005330:0.005330:0.013143:0.007466:0.005330:0.005707:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.013181:0.005330
FEBRILE NEUTROPAENIA:@0.084242:0.145969:0.342946:0.145969:0.342946:0.126372:0.084242:0.126372:0.011289:0.012230:0.013641:0.013641:0.006585:0.010348:0.012230:0.006585:0.017404:0.012230:0.015052:0.009878:0.013641:0.019756:0.013170:0.017404:0.012230:0.017404:0.006585:0.017404
International guidelines define febrile neu-:@0.084242:0.164648:0.475160:0.164648:0.475160:0.148892:0.084242:0.148892:0.004349:0.011738:0.006523:0.012508:0.006186:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.005030:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.005042:0.013181:0.012508:0.004686:0.004686:0.011738:0.012498:0.005032:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.005032:0.011738:0.012508:0.011699:0.006388
tropaenia (FN) as an oral temperature :@0.084242:0.181039:0.480505:0.181039:0.480505:0.165283:0.084242:0.165283:0.006523:0.005709:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.012373:0.007100:0.009333:0.014239:0.007100:0.012373:0.013143:0.007466:0.012373:0.013143:0.011738:0.012373:0.012604:0.005792:0.013143:0.003848:0.012373:0.006523:0.012508:0.018049:0.013123:0.012508:0.005792:0.013143:0.006523:0.011699:0.005705:0.012508:0.005330
of >38.3°C, or of >38.0°C on two or more :@0.084242:0.197430:0.480480:0.197430:0.480480:0.181674:0.084242:0.181674:0.012604:0.006042:0.007316:0.011661:0.010660:0.010660:0.005330:0.010660:0.007697:0.015644:0.005330:0.007316:0.012604:0.005792:0.007312:0.012604:0.006042:0.007322:0.011661:0.010660:0.010660:0.005330:0.010660:0.007697:0.015644:0.007331:0.012604:0.011738:0.007314:0.006523:0.015990:0.012604:0.007316:0.012604:0.005792:0.007314:0.018049:0.012604:0.005707:0.012508:0.005330
consecutive readings at least one hour :@0.084242:0.213821:0.480478:0.213821:0.480478:0.198065:0.084242:0.198065:0.012450:0.012604:0.011738:0.007466:0.012508:0.012450:0.011699:0.006523:0.003848:0.010660:0.012508:0.010814:0.005711:0.012508:0.013143:0.013181:0.003848:0.011738:0.012950:0.007466:0.010814:0.013143:0.006523:0.010814:0.003848:0.012508:0.013143:0.007466:0.006523:0.010814:0.012604:0.011738:0.012508:0.010814:0.011738:0.012604:0.011699:0.005792:0.005330
apart, and an absolute neutrophil count :@0.084242:0.230212:0.480499:0.230212:0.480499:0.214456:0.084242:0.214456:0.013143:0.013123:0.013143:0.005792:0.006523:0.005330:0.008332:0.013143:0.011738:0.013181:0.008332:0.013143:0.011738:0.008332:0.013143:0.013123:0.007466:0.012604:0.003848:0.011699:0.006523:0.012508:0.008332:0.011738:0.012508:0.011699:0.006523:0.005713:0.012604:0.013123:0.011738:0.003848:0.003848:0.008332:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330
(ANC) of <0.5 x 10 /L, or <1.0 x 10 /L and :@0.084242:0.246603:0.480480:0.246576:0.480480:0.230820:0.084242:0.230847:0.007100:0.014239:0.014239:0.015644:0.007100:0.007485:0.012604:0.006042:0.007485:0.011661:0.010660:0.005330:0.010660:0.007485:0.009236:0.007485:0.010660:0.010660:0.006226:0.008409:0.008890:0.005330:0.007485:0.012604:0.005792:0.007485:0.011661:0.010660:0.005330:0.010660:0.007485:0.009236:0.007485:0.010660:0.010660:0.006223:0.008409:0.008890:0.007485:0.013143:0.011738:0.013181:0.643655
9:@0.260030:0.240957:0.266245:0.240957:0.266245:0.231772:0.260030:0.231772:0.006215
9:@0.406087:0.240957:0.412302:0.240957:0.412302:0.231772:0.406087:0.231772:0.006215
expected to fall  below 0.5 x 10 /L over :@0.084241:0.262967:0.480484:0.262962:0.480484:0.247206:0.084241:0.247211:0.012508:0.009236:0.013123:0.012508:0.012450:0.006523:0.012508:0.013181:0.010352:0.006523:0.012604:0.010352:0.006042:0.013143:0.003848:0.003848:0.005330:0.005036:0.013123:0.012508:0.003848:0.012604:0.015990:0.010352:0.010660:0.005330:0.010660:0.010352:0.009236:0.010352:0.010660:0.010660:0.006244:0.008409:0.008890:0.010352:0.012604:0.010660:0.012508:0.005792:0.619818
9:@0.399722:0.257343:0.405937:0.257343:0.405937:0.248157:0.399722:0.248157:0.006215
the following 48 hours.  There has been :@0.084245:0.279353:0.480478:0.279348:0.480478:0.263592:0.084245:0.263597:0.006523:0.011738:0.012508:0.008717:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.008717:0.010660:0.010660:0.008717:0.011738:0.012604:0.011699:0.005792:0.007466:0.005330:0.015532:0.008717:0.008197:0.011738:0.012508:0.005705:0.012508:0.008717:0.011738:0.013143:0.007466:0.008717:0.013123:0.012508:0.012508:0.011738:0.595991
7,8:@0.300579:0.273729:0.316116:0.273729:0.316116:0.264543:0.300579:0.264543:0.006215:0.003107:0.006215
a steady decrease in mortality rates relat-:@0.084248:0.295739:0.475159:0.295739:0.475159:0.279983:0.084248:0.279983:0.013143:0.005896:0.007466:0.006523:0.012508:0.013143:0.013181:0.010314:0.005898:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.005898:0.003848:0.011738:0.005896:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005896:0.005792:0.013143:0.006523:0.012508:0.007466:0.005892:0.005713:0.012508:0.003848:0.013143:0.006523:0.006388
ed to febrile neutropaenia, however, this :@0.084248:0.312130:0.480472:0.312130:0.480472:0.296374:0.084248:0.296374:0.012508:0.013181:0.008024:0.006523:0.012604:0.008024:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.008024:0.011738:0.012508:0.011699:0.006523:0.005707:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.008024:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.003764:0.005330:0.008024:0.006523:0.011738:0.003848:0.007466:0.005330
remains an important  cause of cancer-:@0.084248:0.328520:0.475163:0.328520:0.475163:0.312765:0.084248:0.312765:0.005713:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.010372:0.013143:0.011738:0.010372:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.005330:0.005030:0.012450:0.013143:0.011699:0.007466:0.012508:0.010372:0.012604:0.006042:0.010372:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.006388
related mortality and morbidity, as  well :@0.084248:0.344911:0.480459:0.344911:0.480459:0.329155:0.084248:0.329155:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.011064:0.018049:0.012604:0.005792:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.011064:0.013143:0.011738:0.013181:0.011064:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.010314:0.005330:0.011064:0.013143:0.007466:0.005330:0.005746:0.015990:0.012508:0.003848:0.003848:0.005330
as placing financial strain on health-care :@0.084248:0.361302:0.480488:0.361302:0.480488:0.345546:0.084248:0.345546:0.013143:0.007466:0.007480:0.013123:0.003848:0.013143:0.012450:0.003848:0.011738:0.012950:0.007478:0.004686:0.004686:0.011738:0.013143:0.011738:0.012450:0.003848:0.013143:0.003848:0.007476:0.007466:0.006523:0.005792:0.013143:0.003848:0.011738:0.007472:0.012604:0.011738:0.007468:0.011738:0.012508:0.013143:0.003848:0.006523:0.011738:0.006388:0.012450:0.013143:0.005711:0.012508:0.005330
resources. In addition, dose-delays  and :@0.084248:0.377693:0.480476:0.377693:0.480476:0.361937:0.084248:0.361937:0.005713:0.012508:0.007466:0.012604:0.011699:0.005651:0.012450:0.012508:0.007466:0.005330:0.011834:0.004349:0.011738:0.011834:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.011834:0.013181:0.012604:0.007466:0.012508:0.006388:0.013181:0.012508:0.003848:0.013143:0.010314:0.007466:0.005330:0.006519:0.013143:0.011738:0.013181:0.005330
reductions may translate to compromised :@0.084248:0.394084:0.480478:0.394084:0.480478:0.378328:0.084248:0.378328:0.005713:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005563:0.018049:0.013143:0.010314:0.005569:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.013143:0.006523:0.012508:0.005567:0.006523:0.012604:0.005563:0.012450:0.012604:0.018049:0.013123:0.005709:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330
treatment efficacy. All patients should be :@0.084248:0.410475:0.480493:0.410475:0.480493:0.394719:0.084248:0.394719:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006614:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.010314:0.005330:0.006625:0.014239:0.003848:0.003848:0.006623:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006625:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.006621:0.013123:0.012508:0.005330
fully informed of the risk of febrile neutro-:@0.084248:0.426866:0.475154:0.426866:0.475154:0.411110:0.084248:0.411110:0.006042:0.011699:0.003848:0.003848:0.010314:0.007324:0.003848:0.011738:0.006042:0.012604:0.006325:0.018049:0.012508:0.013181:0.007312:0.012604:0.006042:0.007312:0.006523:0.011738:0.012508:0.007312:0.005792:0.003848:0.007466:0.009660:0.007312:0.012604:0.006042:0.007312:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.007312:0.011738:0.012508:0.011699:0.006523:0.005705:0.012604:0.006388
paenia, the  associated symptoms,  and :@0.084248:0.443257:0.480491:0.443257:0.480491:0.427501:0.084248:0.427501:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.012007:0.006523:0.011738:0.012508:0.005330:0.006658:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.012007:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.005330:0.005330:0.006662:0.013143:0.011738:0.013181:0.005330
how to contact the appropriate services :@0.084248:0.459648:0.480501:0.459648:0.480501:0.443892:0.084248:0.443892:0.011738:0.012604:0.015990:0.007986:0.006523:0.012604:0.007986:0.012450:0.012604:0.011738:0.006523:0.013143:0.012450:0.006523:0.007976:0.006523:0.011738:0.012508:0.007986:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.007986:0.007466:0.012508:0.005792:0.010660:0.003848:0.012450:0.012508:0.007466:0.005330
in the event of concerns.:@0.084248:0.476039:0.316944:0.476039:0.316944:0.460283:0.084248:0.460283:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.012508:0.010660:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.012450:0.012604:0.011738:0.012450:0.012508:0.006156:0.011738:0.007466:0.005330
PATHOPHYSIOLOGY:@0.084242:0.509070:0.286929:0.509070:0.286929:0.491255:0.084242:0.491255:0.011973:0.015822:0.008980:0.014539:0.017960:0.011973:0.014539:0.013256:0.011118:0.005987:0.017960:0.009407:0.017960:0.017960:0.013256
While febrile neutropaenia may compli-:@0.084242:0.526602:0.475144:0.526602:0.475144:0.510846:0.084242:0.510846:0.018473:0.011738:0.003848:0.003848:0.012508:0.010680:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.010680:0.011738:0.012508:0.011699:0.006523:0.005707:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.010680:0.018049:0.013143:0.010314:0.010680:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.006388
cate any chemotherapy  treatment,  the :@0.084242:0.542993:0.480505:0.542993:0.480505:0.527237:0.084242:0.527237:0.012450:0.013143:0.006523:0.012508:0.010333:0.013143:0.011738:0.010314:0.010333:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004990:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330:0.004988:0.006523:0.011738:0.012508:0.005330
risk of febrile neutropaenia increases with :@0.084242:0.559384:0.480513:0.559384:0.480513:0.543628:0.084242:0.543628:0.005792:0.003848:0.007466:0.009660:0.006927:0.012604:0.006042:0.006927:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.006927:0.011738:0.012508:0.011699:0.006523:0.005709:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.006927:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.006927:0.015990:0.003848:0.006523:0.011738:0.005330
the  dose-intensity of  the  chemotherapy :@0.084242:0.575775:0.480501:0.575775:0.480501:0.560019:0.084242:0.560019:0.006523:0.011738:0.012508:0.005330:0.005567:0.013181:0.012604:0.007466:0.012508:0.006388:0.003848:0.011738:0.006523:0.012508:0.011738:0.007466:0.003848:0.006523:0.010314:0.010910:0.012604:0.006042:0.005330:0.005569:0.006523:0.011738:0.012508:0.005330:0.005567:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
regimen  utilised. High-risk regimens, de-:@0.084242:0.592166:0.475156:0.592166:0.475156:0.576410:0.084242:0.576410:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.006744:0.011699:0.006523:0.003848:0.003848:0.003848:0.007466:0.012508:0.013181:0.005330:0.012084:0.013143:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.012084:0.005711:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330:0.012084:0.013181:0.012508:0.006388
fined by ASCO as having a greater than :@0.084242:0.608557:0.480488:0.608557:0.480488:0.592801:0.084242:0.592801:0.004686:0.004686:0.011738:0.012508:0.013181:0.007762:0.013123:0.010314:0.007770:0.014239:0.009583:0.015644:0.016722:0.007772:0.013143:0.007466:0.007776:0.011738:0.013143:0.010660:0.003848:0.011738:0.012950:0.007770:0.013143:0.007774:0.012950:0.005713:0.012508:0.013143:0.006523:0.012508:0.005792:0.007762:0.006523:0.011738:0.013143:0.011738:0.005330
20% associated risk of febrile neutropae-:@0.084242:0.624948:0.475121:0.624948:0.475121:0.609192:0.084242:0.609192:0.010660:0.010660:0.014913:0.008659:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.008659:0.005792:0.003848:0.007466:0.009660:0.008659:0.012604:0.006042:0.008659:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.008659:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.006388
nia,  are commonly used in patients with :@0.084242:0.641339:0.480463:0.641302:0.480463:0.625546:0.084242:0.625583:0.011738:0.003848:0.013143:0.005330:0.006217:0.007697:0.013143:0.005713:0.012508:0.007697:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.003848:0.010314:0.007697:0.011699:0.007466:0.012508:0.013181:0.007697:0.003848:0.011738:0.007697:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007697:0.015990:0.003848:0.006523:0.011738:0.069527
9:@0.118302:0.635683:0.124517:0.635683:0.124517:0.626497:0.118302:0.626497:0.006215
Hodgkin’s lymphoma, non-Hodgkin’s lym-:@0.084245:0.657693:0.475135:0.657693:0.475135:0.641937:0.084245:0.641937:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.006985:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.006975:0.011738:0.012604:0.011738:0.006388:0.013143:0.012594:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.006985:0.003848:0.010314:0.018049:0.006388
phoma, testicular malignancies and soft-:@0.084245:0.674084:0.475164:0.674084:0.475164:0.658328:0.084245:0.658328:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.007822:0.006523:0.012508:0.007466:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.007832:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.003848:0.012508:0.007466:0.007832:0.013143:0.011738:0.013181:0.007832:0.007466:0.012604:0.006042:0.006523:0.006388
tissue sarcomas (for a detailed list of high-:@0.084245:0.690475:0.475160:0.690475:0.475160:0.674719:0.084245:0.674719:0.006523:0.003848:0.007466:0.007466:0.011699:0.012508:0.005869:0.007466:0.013143:0.005655:0.012450:0.012604:0.018049:0.013143:0.007466:0.005857:0.007100:0.006042:0.012604:0.005792:0.005850:0.013143:0.005859:0.013181:0.012508:0.006523:0.013143:0.003848:0.003848:0.012508:0.013181:0.005857:0.003848:0.003848:0.007466:0.006523:0.005869:0.012604:0.006042:0.005852:0.011738:0.003848:0.012950:0.011738:0.006388
risk regimens see NCCN Guidelines Version :@0.084245:0.706866:0.480475:0.706866:0.480475:0.691110:0.084245:0.691110:0.005792:0.003848:0.007466:0.009660:0.004830:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.004830:0.007466:0.012508:0.012508:0.004830:0.014239:0.015644:0.015644:0.014239:0.004830:0.016779:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.004841:0.011565:0.012508:0.005792:0.007466:0.003848:0.012604:0.011738:0.005330
2.2017;  Myeloid Growth  Factors,  MGF-A :@0.084245:0.723257:0.480490:0.723257:0.480490:0.707501:0.084245:0.707501:0.010660:0.005330:0.010660:0.010660:0.010660:0.010660:0.005330:0.005330:0.006323:0.017684:0.010314:0.012508:0.003848:0.012604:0.003848:0.013181:0.011642:0.016779:0.005715:0.012604:0.015990:0.006523:0.011738:0.005330:0.006300:0.009333:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.005330:0.006298:0.017684:0.016779:0.009333:0.006388:0.014239:0.005330
1-4).   Other  factors  increasing  the  risk  of :@0.084245:0.739648:0.480482:0.739616:0.480482:0.723860:0.084245:0.723892:0.010660:0.006388:0.010660:0.007100:0.005330:0.012440:0.005330:0.002915:0.016722:0.006523:0.011738:0.012508:0.005792:0.005330:0.002904:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.002909:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.003848:0.011738:0.012950:0.005330:0.002911:0.006523:0.011738:0.012508:0.005330:0.002908:0.005792:0.003848:0.007466:0.009660:0.005330:0.002915:0.012604:0.006042:-0.073494
10:@0.124390:0.733997:0.136820:0.733997:0.136820:0.724811:0.124390:0.724811:0.006215:0.006215
febrile neutropaenia include advanced :@0.084235:0.756007:0.480463:0.756007:0.480463:0.740251:0.084235:0.740251:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.011892:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.011892:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.011892:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330
age  (>65 years), history  of  previous fe-:@0.084235:0.772398:0.475150:0.772398:0.475150:0.756642:0.084235:0.756642:0.013143:0.012950:0.012508:0.005330:0.006514:0.007100:0.011661:0.010660:0.010660:0.011853:0.010314:0.012508:0.013143:0.005792:0.007466:0.007100:0.005330:0.011853:0.011738:0.003848:0.007466:0.006523:0.012604:0.005792:0.010314:0.005330:0.006512:0.012604:0.006042:0.005330:0.006512:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.011853:0.006042:0.012508:0.006388
brile neutropaenia, poor  performance :@0.084235:0.788789:0.480484:0.788789:0.480484:0.773033:0.084235:0.773033:0.013123:0.005792:0.003848:0.003848:0.012508:0.016298:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.016298:0.013123:0.012604:0.012604:0.005792:0.005330:0.010953:0.013123:0.012508:0.006706:0.006042:0.012604:0.006319:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330
status, extensive  prior  therapy, extensive :@0.084235:0.805180:0.480492:0.805180:0.480492:0.789424:0.084235:0.789424:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330:0.009794:0.012508:0.009236:0.006523:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330:0.004455:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.004453:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.009794:0.012508:0.009236:0.006523:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330
bone-marrow  infiltration  and  significant :@0.084235:0.821571:0.480475:0.821571:0.480475:0.805815:0.084235:0.805815:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005705:0.012604:0.015990:0.005330:0.009054:0.003848:0.011738:0.004686:0.004686:0.003848:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.009050:0.013143:0.011738:0.013181:0.005330:0.009057:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330
comorbidities.:@0.084235:0.837962:0.215410:0.837962:0.215410:0.822206:0.084235:0.822206:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330
7:@0.215416:0.832311:0.221631:0.832311:0.221631:0.823125:0.215416:0.823125:0.006215
Contributory  factors  to  the pathogen-:@0.102424:0.854315:0.475150:0.854315:0.475150:0.838559:0.102424:0.838559:0.015644:0.012604:0.011738:0.006523:0.005792:0.003848:0.013123:0.011699:0.006523:0.012604:0.005792:0.010314:0.005330:0.005138:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330:0.005147:0.006523:0.012604:0.005330:0.005147:0.006523:0.011738:0.012508:0.010487:0.013123:0.013143:0.006523:0.011738:0.012604:0.012950:0.012508:0.011719:0.006388
esis of  febrile neutropaenia  include the :@0.084240:0.870706:0.480501:0.870706:0.480501:0.854950:0.084240:0.854950:0.012508:0.007466:0.003848:0.007466:0.011007:0.012604:0.006042:0.005330:0.005661:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.011007:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005667:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.011007:0.006523:0.011738:0.012508:0.005330
immunosuppressive effects  of  chemo-:@0.084240:0.887097:0.475150:0.887097:0.475150:0.871341:0.084240:0.871341:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.007466:0.011699:0.013123:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.017799:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.012458:0.012604:0.006042:0.005330:0.012454:0.012450:0.011738:0.012508:0.018049:0.012596:0.006388
therapy,  direct  effects  of  chemotherapy :@0.084240:0.903488:0.480499:0.903488:0.480499:0.887732:0.084240:0.887732:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.003543:0.013181:0.003848:0.005717:0.012508:0.012450:0.006523:0.005330:0.003550:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.003546:0.012604:0.006042:0.005330:0.003544:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
on  the  mucosal barriers  with seeding of :@0.084240:0.919879:0.480501:0.919879:0.480501:0.904123:0.084240:0.904123:0.012604:0.011738:0.005330:0.004355:0.006523:0.011738:0.012508:0.005330:0.004355:0.018049:0.011699:0.012450:0.012604:0.007466:0.013143:0.003848:0.009698:0.013123:0.013143:0.005792:0.005792:0.003848:0.012508:0.005792:0.007466:0.005330:0.004358:0.015990:0.003848:0.006523:0.011738:0.009698:0.007466:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.009698:0.012604:0.006042:0.005330
the  bloodstream  with  endogenous  flora, :@0.084240:0.936270:0.480489:0.936270:0.480489:0.920514:0.084240:0.920514:0.006523:0.011738:0.012508:0.005330:0.004193:0.013123:0.003848:0.012604:0.012604:0.013181:0.007466:0.006523:0.005711:0.012508:0.013143:0.018049:0.005330:0.004199:0.015990:0.003848:0.006523:0.011738:0.005330:0.004199:0.012508:0.011738:0.013181:0.012604:0.012941:0.012508:0.011738:0.012604:0.011699:0.007466:0.005330:0.004193:0.004666:0.004666:0.012604:0.005792:0.013143:0.005330:0.005330
breech in host defences related to  the :@0.523640:0.096192:0.919907:0.096192:0.919907:0.080436:0.523640:0.080436:0.013123:0.005715:0.012508:0.012508:0.012450:0.011738:0.010545:0.003848:0.011738:0.010545:0.011738:0.012604:0.007466:0.006523:0.010545:0.013181:0.012508:0.006042:0.012508:0.011738:0.012450:0.012508:0.007466:0.010545:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.010545:0.006523:0.012604:0.005330:0.005205:0.006523:0.011738:0.012508:0.005330
underlying malignancy and obstruction :@0.523640:0.112609:0.919899:0.112609:0.919899:0.096853:0.523640:0.096853:0.011699:0.011738:0.013181:0.012508:0.005792:0.003848:0.010314:0.003848:0.011738:0.012950:0.013220:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.013220:0.013143:0.011738:0.013181:0.013220:0.012604:0.013123:0.007466:0.006523:0.005792:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
of lymphatics and hollow organs (biliary :@0.523640:0.129026:0.919822:0.129026:0.919822:0.113270:0.523640:0.113270:0.012604:0.006042:0.009660:0.003848:0.010314:0.018049:0.013123:0.011738:0.013143:0.006523:0.003848:0.012450:0.007466:0.009660:0.013143:0.011738:0.013181:0.009660:0.011738:0.012604:0.003848:0.003848:0.012604:0.015990:0.009660:0.012604:0.005792:0.012950:0.013143:0.011738:0.007466:0.009660:0.007100:0.013123:0.003848:0.003848:0.003848:0.013143:0.005792:0.010314:0.005330
tract, bronchial, gastro-intestinal or urinary :@0.523640:0.145444:0.919888:0.145444:0.919888:0.129688:0.523640:0.129688:0.006523:0.005792:0.013143:0.012450:0.006523:0.005330:0.005224:0.013123:0.005715:0.012604:0.011738:0.012450:0.011738:0.003848:0.013143:0.003848:0.005330:0.005234:0.012950:0.013143:0.007466:0.006523:0.005713:0.012604:0.006388:0.003848:0.011738:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.005234:0.012604:0.005792:0.005234:0.011699:0.005792:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330
tracts) by tumours or surgical procedures. :@0.523640:0.161861:0.919892:0.161861:0.919892:0.146105:0.523640:0.146105:0.006523:0.005792:0.013143:0.012450:0.006523:0.007466:0.007100:0.006550:0.013123:0.010314:0.006562:0.006523:0.011699:0.018049:0.012594:0.011699:0.005792:0.007466:0.006548:0.012604:0.005792:0.006542:0.007466:0.011699:0.005809:0.012950:0.003848:0.012450:0.013143:0.003848:0.006562:0.013123:0.005715:0.012604:0.012450:0.012508:0.013181:0.011699:0.005705:0.012508:0.007466:0.005330:0.005330
As a result, infectious pathogens may be :@0.523640:0.178279:0.919897:0.178279:0.919897:0.162523:0.523640:0.162523:0.014239:0.007466:0.007553:0.013143:0.007562:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.005330:0.007553:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011699:0.007466:0.007553:0.013123:0.013143:0.006523:0.011738:0.012604:0.012950:0.012508:0.011738:0.007466:0.007553:0.018049:0.013143:0.010314:0.007562:0.013123:0.012508:0.005330
bacterial, fungal and occasionally viral.:@0.523640:0.194696:0.892229:0.194696:0.892229:0.178940:0.523640:0.178940:0.013123:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.013143:0.003848:0.005330:0.005330:0.006042:0.011699:0.011738:0.012950:0.013143:0.003848:0.005330:0.013143:0.011738:0.013181:0.005330:0.012604:0.012450:0.012450:0.013143:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.003848:0.010314:0.005330:0.010660:0.003848:0.005792:0.013143:0.003848:0.005330
PREVENTION:@0.523636:0.227805:0.649781:0.227805:0.649781:0.209990:0.523636:0.209990:0.011973:0.012401:0.011118:0.014966:0.011118:0.015822:0.008980:0.005987:0.017960:0.015822
Preventive  strategies  include  chemopro-:@0.523636:0.245366:0.914545:0.245366:0.914545:0.229610:0.523636:0.229610:0.011392:0.005709:0.012508:0.010660:0.012508:0.011738:0.006523:0.003848:0.010660:0.012508:0.005330:0.004566:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.012950:0.003848:0.012508:0.007466:0.005330:0.004564:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.005330:0.004566:0.012450:0.011738:0.012508:0.018049:0.012604:0.013123:0.005705:0.012604:0.006388
phylaxis and/or  prophylaxis with G-CSF :@0.523636:0.261783:0.919866:0.261783:0.919866:0.246027:0.523636:0.246027:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.013335:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.005330:0.007995:0.013123:0.005715:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.013335:0.015990:0.003848:0.006523:0.011738:0.013335:0.016779:0.006388:0.015644:0.009583:0.009333:0.005330
(filgrastim  or  pegfilgrastim).  Chemopro-:@0.523636:0.278201:0.914547:0.278201:0.914547:0.262445:0.523636:0.262445:0.007100:0.004686:0.004686:0.003848:0.012950:0.005792:0.013143:0.007466:0.006523:0.003848:0.018049:0.005330:0.009361:0.012604:0.005792:0.005330:0.009350:0.013123:0.012508:0.012950:0.004686:0.004686:0.003848:0.012950:0.005792:0.013143:0.007466:0.006523:0.003848:0.018049:0.007100:0.005330:0.005330:0.009356:0.015644:0.011738:0.012508:0.018049:0.012604:0.013123:0.005705:0.012604:0.006388
phylaxis  with broad-spectrum antibiotics :@0.523636:0.294618:0.919872:0.294618:0.919872:0.278862:0.523636:0.278862:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.005330:0.005750:0.015990:0.003848:0.006523:0.011738:0.011064:0.013123:0.005715:0.012604:0.013143:0.013181:0.006388:0.007466:0.013123:0.012508:0.012450:0.006523:0.005792:0.011699:0.018049:0.011064:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.012604:0.006523:0.003848:0.012450:0.007466:0.005330
carries the risk of antibiotic-resistant strains, :@0.523636:0.311035:0.919887:0.311035:0.919887:0.295279:0.523636:0.295279:0.012450:0.013143:0.005792:0.005792:0.003848:0.012508:0.007466:0.004695:0.006523:0.011738:0.012508:0.004686:0.005792:0.003848:0.007466:0.009660:0.004695:0.012604:0.006042:0.004695:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.012604:0.006523:0.003848:0.012450:0.006388:0.005717:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.004695:0.007466:0.006523:0.005792:0.013143:0.003848:0.011738:0.007466:0.005330:0.005330
and current guidelines from the European :@0.523636:0.327453:0.919902:0.327453:0.919902:0.311697:0.523636:0.311697:0.013143:0.011738:0.013181:0.005773:0.012450:0.011699:0.005792:0.005713:0.012508:0.011738:0.006523:0.005759:0.012950:0.011699:0.003848:0.013181:0.012508:0.003848:0.003848:0.011738:0.012508:0.007466:0.005773:0.006042:0.005713:0.012604:0.018049:0.005761:0.006523:0.011738:0.012508:0.005773:0.010314:0.011699:0.005713:0.012604:0.013123:0.012508:0.013143:0.011738:0.005330
Organisation for Research and Treatment :@0.523636:0.343870:0.919887:0.343870:0.919887:0.328114:0.523636:0.328114:0.016722:0.005809:0.012950:0.013143:0.011738:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.006856:0.006042:0.012604:0.005792:0.006852:0.011680:0.012508:0.007466:0.012508:0.013143:0.005657:0.012450:0.011738:0.006852:0.013143:0.011738:0.013181:0.006858:0.007620:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of Cancer (EORTC) and American So-:@0.523636:0.360288:0.914541:0.360288:0.914541:0.344532:0.523636:0.344532:0.012604:0.006042:0.013143:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.013143:0.007100:0.010314:0.016722:0.011792:0.008197:0.015644:0.007100:0.013143:0.013143:0.011738:0.013181:0.013143:0.014239:0.018049:0.012508:0.005792:0.003848:0.012450:0.013143:0.011738:0.013143:0.009583:0.012604:0.006388
ciety  of  Clinical Oncology  (ASCO)  rec-:@0.523636:0.376705:0.914545:0.376705:0.914545:0.360949:0.523636:0.360949:0.012450:0.003848:0.012508:0.006523:0.010314:0.005330:0.006185:0.012604:0.006042:0.005330:0.006179:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.011526:0.016722:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.006179:0.007100:0.014239:0.009583:0.015644:0.016722:0.007100:0.005330:0.006186:0.005713:0.012508:0.012450:0.006388
ommend  that  clinicians limit  the  use  of :@0.523636:0.393122:0.919870:0.393122:0.919870:0.377366:0.523636:0.377366:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.005330:0.005540:0.006523:0.011738:0.013143:0.006523:0.005330:0.005544:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.003848:0.013143:0.011738:0.007466:0.010891:0.003848:0.003848:0.018049:0.003848:0.006523:0.005330:0.005550:0.006523:0.011738:0.012508:0.005330:0.005542:0.011699:0.007466:0.012508:0.005330:0.005548:0.012604:0.006042:0.005330
antibacterial prophylaxis to  patients with :@0.523636:0.409540:0.919860:0.409540:0.919860:0.393784:0.523636:0.393784:0.013143:0.011738:0.006523:0.003848:0.013123:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.013143:0.003848:0.008755:0.013123:0.005711:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.008755:0.006523:0.012604:0.005330:0.003414:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008755:0.015990:0.003848:0.006523:0.011738:0.005330
>20% risk of febrile neutropaenia, or where :@0.523636:0.425957:0.919883:0.425957:0.919883:0.410201:0.523636:0.410201:0.011661:0.010660:0.010660:0.014913:0.004926:0.005792:0.003848:0.007466:0.009660:0.004913:0.012604:0.006042:0.004909:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.004916:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.004916:0.012604:0.005792:0.004905:0.015990:0.011738:0.012508:0.005709:0.012508:0.005330
specific  indications  exist  (such  as  valaci-:@0.523636:0.442374:0.914545:0.442374:0.914545:0.426619:0.523636:0.426619:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330:0.003702:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.003696:0.012508:0.009236:0.003848:0.007466:0.006523:0.005330:0.003702:0.007100:0.007466:0.011699:0.012450:0.011738:0.005330:0.003700:0.013143:0.007466:0.005330:0.003704:0.010660:0.013143:0.003848:0.013143:0.012450:0.003873:0.006388
clovir for  patients  receiving bortezomib-:@0.523636:0.458792:0.914572:0.458792:0.914572:0.443036:0.523636:0.443036:0.012450:0.003848:0.012604:0.010660:0.003848:0.005792:0.010872:0.006042:0.012604:0.005792:0.005330:0.005526:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005530:0.005711:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.010872:0.013123:0.012604:0.005792:0.006523:0.012508:0.008178:0.012604:0.018049:0.003848:0.013123:0.006388
containing  regimens, and trimethoprim-:@0.523636:0.475209:0.914568:0.475209:0.914568:0.459453:0.523636:0.459453:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.007127:0.005711:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330:0.012469:0.013143:0.011738:0.013181:0.012469:0.006523:0.005792:0.003848:0.018049:0.012508:0.006523:0.011738:0.012604:0.013123:0.005792:0.003848:0.018049:0.006388
sulfamethoxazole  for  patients receiving :@0.523636:0.491627:0.919874:0.491627:0.919874:0.475871:0.523636:0.475871:0.007466:0.011699:0.003848:0.006042:0.013143:0.018049:0.012508:0.006523:0.011738:0.012604:0.009236:0.013143:0.008178:0.012604:0.003848:0.012508:0.005330:0.008746:0.006042:0.012604:0.005792:0.005330:0.008746:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.014085:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.005330
temozolomide).:@0.523636:0.508044:0.670571:0.508044:0.670571:0.492288:0.523636:0.492288:0.006523:0.012508:0.018049:0.012604:0.008178:0.012604:0.003848:0.012604:0.018049:0.003848:0.013181:0.012508:0.007100:0.005330
9,11:@0.670556:0.502378:0.692309:0.502378:0.692309:0.493193:0.670556:0.493193:0.006215:0.003107:0.006215:0.006215
 :@0.692314:0.507997:0.697644:0.507997:0.697644:0.492242:0.692314:0.492242:0.005330
Similarly, primary G-CSF prophylaxis (ini-:@0.541819:0.524415:0.914525:0.524415:0.914525:0.508659:0.541819:0.508659:0.009583:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.003848:0.010314:0.005330:0.007562:0.013123:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.007553:0.016779:0.006388:0.015644:0.009583:0.009333:0.007553:0.013123:0.005715:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.007562:0.007100:0.003848:0.011738:0.003848:0.006388
tiated  with  first  cycle  of  chemotherapy) :@0.523635:0.540832:0.919884:0.540832:0.919884:0.525076:0.523635:0.525076:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.004699:0.015990:0.003848:0.006523:0.011738:0.005330:0.004699:0.004686:0.004686:0.005792:0.007466:0.006523:0.005330:0.004691:0.012450:0.010314:0.012450:0.003848:0.012508:0.005330:0.004703:0.012604:0.006042:0.005330:0.004693:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007100:0.005330
should be limited to those with >20% risk :@0.523635:0.557250:0.919874:0.557250:0.919874:0.541494:0.523635:0.541494:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.008601:0.013123:0.012508:0.008601:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.008601:0.006523:0.012604:0.008601:0.006523:0.011738:0.012604:0.007466:0.012508:0.008601:0.015990:0.003848:0.006523:0.011738:0.008601:0.011661:0.010660:0.010660:0.014913:0.008601:0.005792:0.003848:0.007466:0.009660:0.005330
of febrile neutropaenia, while secondary :@0.523635:0.573667:0.919882:0.573667:0.919882:0.557911:0.523635:0.557911:0.012604:0.006042:0.008467:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.008467:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.008467:0.015990:0.011738:0.003848:0.003848:0.012508:0.008467:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.013143:0.005792:0.010314:0.005330
prophylaxis (initiated with the second- or :@0.523635:0.590084:0.919886:0.590084:0.919886:0.574329:0.523635:0.574329:0.013123:0.005715:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.009236:0.003848:0.007466:0.008190:0.007100:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.008178:0.015990:0.003848:0.006523:0.011738:0.008178:0.006523:0.011738:0.012508:0.008178:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.008178:0.012604:0.005792:0.005330
subsequent cycles of chemotherapy) :@0.523635:0.606502:0.919874:0.606502:0.919874:0.590746:0.523635:0.590746:0.007466:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.019262:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.019262:0.012604:0.006042:0.019262:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007100:0.005330
should be commenced in any patient with :@0.523635:0.622919:0.919894:0.622919:0.919894:0.607163:0.523635:0.607163:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.004156:0.013123:0.012508:0.004156:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.012450:0.012508:0.013181:0.004156:0.003848:0.011738:0.004156:0.013143:0.011738:0.010314:0.004156:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.004156:0.015990:0.003848:0.006523:0.011738:0.005330
a history of previous febrile neutropaenia, :@0.523635:0.639337:0.919888:0.639337:0.919888:0.623581:0.523635:0.623581:0.013143:0.006388:0.011738:0.003848:0.007466:0.006523:0.012604:0.005792:0.010314:0.006388:0.012604:0.006042:0.006388:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.006388:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.006388:0.011738:0.012508:0.011699:0.006523:0.005709:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330
while on active treatment.:@0.523635:0.655754:0.769580:0.655754:0.769580:0.639998:0.523635:0.639998:0.015990:0.011738:0.003848:0.003848:0.012508:0.005330:0.012604:0.011738:0.005330:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.005330:0.006523:0.005703:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
PRESENTING SIGNS AND SYMPTOMS:@0.523636:0.688880:0.885393:0.688880:0.885393:0.671065:0.523636:0.671065:0.011973:0.012401:0.011118:0.011118:0.011118:0.015822:0.008980:0.005987:0.015822:0.017960:0.005987:0.011118:0.005987:0.017960:0.015822:0.011118:0.005987:0.015822:0.015822:0.014966:0.005987:0.011118:0.013256:0.019242:0.011973:0.008980:0.017960:0.019242:0.011118
The magnitude of the neutrophil-mediat-:@0.523636:0.706441:0.914549:0.706441:0.914549:0.690685:0.523636:0.690685:0.008197:0.011738:0.012508:0.008009:0.018049:0.013143:0.012950:0.011738:0.003848:0.006523:0.011699:0.013181:0.012508:0.008024:0.012604:0.006042:0.008011:0.006523:0.011738:0.012508:0.008011:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.011738:0.003848:0.003848:0.006388:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.006388
ed inflammatory response may be muted :@0.523636:0.722859:0.919879:0.722859:0.919879:0.707103:0.523636:0.707103:0.012508:0.013181:0.006094:0.003848:0.011738:0.004666:0.004666:0.013143:0.018049:0.018049:0.013143:0.006523:0.012604:0.005792:0.010314:0.006086:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.006094:0.018049:0.013143:0.010314:0.006098:0.013123:0.012508:0.006094:0.018049:0.011699:0.006523:0.012508:0.013181:0.005330
in neutropaenic patients, and thus an :@0.523636:0.739276:0.919873:0.739276:0.919873:0.723520:0.523636:0.723520:0.003848:0.011738:0.013431:0.011738:0.012508:0.011699:0.006523:0.005713:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.012450:0.013431:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.013431:0.013143:0.011738:0.013181:0.013431:0.006523:0.011738:0.011699:0.007466:0.013431:0.013143:0.011738:0.005330
increase in temperature is often the ear-:@0.523636:0.755693:0.914572:0.755693:0.914572:0.739937:0.523636:0.739937:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.008101:0.003848:0.011738:0.008101:0.006523:0.012508:0.018049:0.013123:0.012508:0.005792:0.013143:0.006523:0.011699:0.005705:0.012508:0.008091:0.003848:0.007466:0.008101:0.012604:0.006042:0.006523:0.012508:0.011738:0.008086:0.006523:0.011738:0.012508:0.008088:0.012508:0.013143:0.005792:0.006388
liest sign of infection.  It is thus critical to :@0.523636:0.772111:0.919883:0.772111:0.919883:0.756355:0.523636:0.756355:0.003848:0.003848:0.012508:0.007466:0.006523:0.009352:0.007466:0.003848:0.012950:0.011738:0.009352:0.012604:0.006042:0.009352:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.004010:0.004349:0.006523:0.009352:0.003848:0.007466:0.009352:0.006523:0.011738:0.011699:0.007466:0.009352:0.012450:0.005792:0.003848:0.006523:0.003848:0.012450:0.013143:0.003848:0.009352:0.006523:0.012604:0.005330
recognise potential neutropaenic fever :@0.523636:0.788528:0.919881:0.788528:0.919881:0.772772:0.523636:0.772772:0.005713:0.012508:0.012450:0.012604:0.012950:0.011738:0.003848:0.007466:0.012508:0.013393:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.013393:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.012450:0.013393:0.006042:0.012508:0.010660:0.012508:0.005792:0.005330
syndromes and react timeously. Prompt :@0.523636:0.804946:0.919869:0.804946:0.919869:0.789190:0.523636:0.789190:0.007466:0.010314:0.011738:0.013181:0.005717:0.012604:0.018049:0.012508:0.007466:0.010968:0.013143:0.011738:0.013181:0.010968:0.005713:0.012508:0.013143:0.012450:0.006523:0.010968:0.006523:0.003848:0.018049:0.012508:0.012604:0.011699:0.007466:0.003848:0.010314:0.005330:0.010968:0.011392:0.005709:0.012604:0.018049:0.013123:0.006523:0.005330
recognition and early initiation of empiric :@0.523636:0.821363:0.919883:0.821363:0.919883:0.805607:0.523636:0.805607:0.005713:0.012508:0.012450:0.012604:0.012950:0.011738:0.003848:0.006523:0.003848:0.012604:0.011738:0.006947:0.013143:0.011738:0.013181:0.006966:0.012508:0.013143:0.005792:0.003848:0.010314:0.006966:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006966:0.012604:0.006042:0.006956:0.012508:0.018049:0.013123:0.003848:0.005792:0.003848:0.012450:0.005330
systemic antibacterial therapy are essen-:@0.523636:0.837780:0.914555:0.837780:0.914555:0.822024:0.523636:0.822024:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.007524:0.013143:0.011738:0.006523:0.003848:0.013123:0.013143:0.012450:0.006523:0.012508:0.005792:0.003848:0.013143:0.003848:0.007524:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007524:0.013143:0.005715:0.012508:0.007514:0.012508:0.007466:0.007466:0.012508:0.011738:0.006388
tial in  improving  outcomes  related to  fe-:@0.523636:0.854198:0.914561:0.854198:0.914561:0.838442:0.523636:0.838442:0.006523:0.003848:0.013143:0.003848:0.008351:0.003848:0.011738:0.005330:0.003011:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.003848:0.011738:0.012950:0.005330:0.003008:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.007466:0.005330:0.002998:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.008351:0.006523:0.012604:0.005330:0.003004:0.006042:0.012508:0.006388
brile neutropaenia, and a delay in initiation :@0.523636:0.870615:0.919896:0.870615:0.919896:0.854859:0.523636:0.854859:0.013123:0.005792:0.003848:0.003848:0.012508:0.003464:0.011738:0.012508:0.011699:0.006523:0.005711:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.003450:0.013143:0.011738:0.013181:0.003454:0.013143:0.003464:0.013181:0.012508:0.003848:0.013143:0.010314:0.003464:0.003848:0.011738:0.003454:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
of antibiotic treatment  has been shown :@0.523636:0.887032:0.919879:0.887032:0.919879:0.871277:0.523636:0.871277:0.012604:0.006042:0.009929:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.012604:0.006523:0.003848:0.012450:0.009929:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.004589:0.011738:0.013143:0.007466:0.009929:0.013123:0.012508:0.012508:0.011738:0.009929:0.007466:0.011738:0.012604:0.015990:0.011738:0.005330
to  be  associated  with  a  significantly  in-:@0.523636:0.903450:0.914532:0.903450:0.914532:0.887694:0.523636:0.887694:0.006523:0.012604:0.005330:0.005222:0.013123:0.012508:0.005330:0.005230:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.005228:0.015990:0.003848:0.006523:0.011738:0.005330:0.005228:0.013143:0.005330:0.005232:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.005330:0.005230:0.003848:0.011738:0.006388
creased hospital stay and increased mor-:@0.523636:0.919867:0.914545:0.919867:0.914545:0.904111:0.523636:0.904111:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.006158:0.011738:0.012604:0.007466:0.013123:0.003848:0.006523:0.013143:0.003848:0.006158:0.007466:0.006523:0.013143:0.010314:0.006158:0.013143:0.011738:0.013181:0.006158:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.006158:0.018049:0.012604:0.005757:0.006388
tality.  See Figure 2 for a consensus-based :@0.523636:0.936285:0.919866:0.936244:0.919866:0.920488:0.523636:0.920529:0.006523:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330:0.006221:0.005888:0.009583:0.012508:0.012508:0.005888:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.005888:0.010660:0.005888:0.006042:0.012604:0.005792:0.005879:0.013143:0.005888:0.012450:0.012604:0.011738:0.007466:0.012508:0.011738:0.007466:0.011699:0.007466:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:-0.798882
7:@0.573170:0.930625:0.579385:0.930625:0.579385:0.921439:0.573170:0.921439:0.006215